Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Phase III NALA trial

Medicine & Life Sciences

• N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide 100%
• Lapatinib 80%
• Capecitabine 72%
• Central Nervous System Diseases 62%
• Progression-Free Survival 51%
• Breast Neoplasms 36%
• Protein-Tyrosine Kinases 26%
• Loperamide 20%
• Quality of Life 18%
• Asymptomatic Diseases 18%
• Safety 16%
• Survival 15%
• Nausea 12%
• Diarrhea 11%
• Research Personnel 9%
• Incidence 6%